Block Admission Return

October 03, 2016
Proteome Sciences Block Admission Return.

Spectrometry Technique Enhances Detection of Early Stage AD Biomarkers

September 22, 2016

“This study clearly demonstrates the potential of combined tissue and fluid proteomics to discover and validate low abundant, tissue-derived biomarkers in peripheral fluids, which in this case resulted in the widest coverage of both tau and phosphorylated tau in human cerebrospinal fluid.

Stacking the Odds in Alzheimer's Disease Drug Development

September 20, 2016

We have been developing several drugs that modulate the phosphorylation of the aggregating protein tau in Alzheimer’s disease by inhibiting the protein casein kinase 1 delta. We have tested them in a model of human tauopathy (aggregating tau diseases) and analyzed brain tissue with SysQuant® to determine the drug’s mechanism of action.

Proteome Sciences Interim Results

September 15, 2016
“We are pleased to report that performance during the first six months of 2016 has been in line with expectations, and it is encouraging that revenues remain well ahead of the equivalent period in 2015

Trading Update and Notice of Results

July 28, 2016

Revenues in the first half are significantly ahead of the equivalent period in 2015 driven principally by strong sales of our TMT® reagents.

AGM Statement and Result of AGM

June 24, 2016
At the AGM held earlier today it was announced that revenues from the core biomarker services activities remained buoyant in the first half with a strong order book, including repeat business, and a developing pipeline. TMT revenue growth has continued into 2016 and TMT was highly visible at the recent meeting of the American Society for Mass Spectrometry. The growing recognition of tau as a…

Publication of Annual Reports and Accounts 2015

June 01, 2016
The Company announces that its Annual Report and Accounts for the year ended 31 December 2015, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company’s website at, and will be posted to shareholders imminently.

CEO Appointment

June 01, 2016

We are pleased to announce the appointment of Jeremy Haigh as a director and CEO of the Company on 1st June 2016 as indicated in the press release to shareholders dated 18th May 2016. He is a strong advocate of Precision Medicine and will bring numerous industry contacts and considerable commercial experience to the role.

Adding Precision to Medicine - Annual Report and Accounts 2015

May 31, 2016
We have benefitted from a good performance in all aspects of the business in 2015, in particular biomarker services where there has been strong customer adoption of SysQuant® and TMTcalibrator™ with the focus on Precision Medicine. Considerable scientific progress has been made over the period, particularly in Alzheimer’s disease (Ad) across a number of different areas and these have formed…

CEO Appointment

May 18, 2016

Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.